P

Panax Clinical Research | Miami Lakes, FL

Research site
(Unclaimed)
Location
14600 NW 60th Avenue, Unit B, Miami Lakes, Florida, United States of America
Site insights

Top conditions

Fatty Liver (9 trials)

Non-alcoholic Fatty Liver Disease (9 trials)

Liver Diseases (6 trials)

Type 2 Diabetes Mellitus (6 trials)

Diabetes Mellitus (6 trials)

Top treatments

SEL-212
ALT-801
BI 685509
Nitazoxanide
Amisulpride
HU6
Relamorelin
Estradiol
AXA1125
Tirzepatide

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

13 of 47
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function

The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body...

Enrolling
Chronic Hepatitis D Infection
Drug: Bulevirtide (BLV)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to...

Enrolling
COVID-19
Influenza
Biological: Placebo
Biological: Influenza and COVID-19 Combination B

This study is open to adults who are at least 18 years old and havepresumed or confirmed NASH together with overweight or obesity anda body mass inde...

Enrolling
Non-Alcoholic SteatoHepatitis (NASH)
Obesity
Drug: Placebo
Drug: Survodutide

A phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver...

Active, not recruiting
Nonalcoholic Steatohepatitis (NASH)
Type 2 Diabetes
Drug: Placebo
Drug: HTD1801

The primary objective of this study is to evaluate the safety and tolerability of intravenous (IV) IMM-BCP-01 in subjects with mild to moderate COVID...

Enrolling
COVID-19
SARS-CoV2 Infection
Drug: Placebo
Drug: IMM-BCP-01

A open label multi-center 3-period multidose, PK/PD and drug-drug interaction (DDI) study to evaluate the pharmacokinetics (PK) and pharmacodynamics...

Enrolling
Hyperuricemia
Gout
Drug: allopurinol
Drug: dontinurad

This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepat...

Enrolling
Fatty Liver
Nonalcoholic Steatohepatitis
Other: Placebo
Drug: HU6

This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (stea...

Enrolling
Non Alcoholic Steatohepatitis (NASH)
Drug: AXA1125
Drug: Placebo

A Phase 1/ 2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokine...

Enrolling
Type 2 Diabetes Mellitus
Drug: BMF-219

The purpose of the present study is to assess the efficacy of secukinumab 300 mg s.c. (subcutaneous) compared to placebo, each in combination with st...

Enrolling
Rotator Cuff Tendinopathy
Drug: Secukinumab
Drug: Placebo

This is a double-blinded, two-arm, phase II study to assess efficacy, safety and tolerability of DFV890 in participants with symptomatic knee osteoar...

Enrolling
Symptomatic Knee Osteoarthritis
Drug: Placebo
Drug: DFV890

This is a non-randomized, open-label, single arm, self-controlled study of XP-8121 (levothyroxine sodium) to determine a target dose conversion facto...

Active, not recruiting
Hypothyroidism
Drug: levothyroxine sodium

Trial sponsors

Boehringer Ingelheim logo

Boehringer Ingelheim (4 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems